They have a great product treating cancer with immunotherapy, peer reviewed journal

look into Adamis Pharma, no more speculation, now it's real, two FDA approved meds, two major products, top of the line in comparison of their rivals, for cheaper price, AND WITH NO MUCH COMPETITION!

2023 is going to be very positive for patients of our products and shareholders alike

Their product works (see the mad Pole Piotr’s graphs 😵‍💫) Multi year holds, the bodadem.

We have great data out of a superior product,

They have good products and a solid future.

$BXRX Even if they don't sell Anjeso, the product is unique in a market with great potential.

$EMED QB ticker announced new product , .01-.03 nice % incoming i believe

$BXRX THE COMPANY HAS AN EXCELLENT PRODUCT MILOXICAM IV FOR PAIN RELIEF.

A unique product on the market that will soon be marketed internationally as well.

$XERS their primary product increases 9% week to week sales with an overall trend that's incredible.

$XERS I like their products and the inject opportunity with Horizon Tepezza is huge I wish they weren't acquired so they can keep a focus on that.

Earnings are growing and there could be great news any day from a variety of sources, whether a collab exercise of option, new product collab, royalty pmt, etc.

More important is that they grow Recorlev's revenue at high(er) speed, and continue to gain market share with Gvoke without product price drop.

Revenue exploding on the upside with their 4 products.

Even if they have more short term gains coming soon, we know the Gvoke product will gain share back due to the more pleasant experience. Patience.

Gvoke is the best and easiest product out there.

Products have been approved and much more is coming, wait and relax.

For a tiny company like xeris to go toe to toe with lilly and grow share shows they have the best product.

$XERS Truly so strange, everything Xeris had in its programme has been met, briefly 3 FDA approved products, collaborations with major pharmacies and much, much more.